Partners
Diamond
AstraZeneca
We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally.
We have three priorities designed to deliver our growth through innovation strategy.
Accelerate Innovative Science:
Accelerating the next wave of new molecular entities, building our capabilities in immunology and rare diseases, pursuing new scientific modalities and driving R&D productivity
Deliver Growth and Therapy Area Leadership:
Meeting our growth and profitability goals through successful innovation and commercial excellence, as well as completing the Alexion acquisition
Be a Great Place to Work:
Contributing to the enterprise and to society, with a focus on inclusion and diversity, lifelong learning, improving access to healthcare, environmental protection, and ethics and transparency, as well as delivering our Ambition Zero Carbon program.
Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.
We are committed to operating in a way that recognizes the interconnection between business growth, the needs of society and the limitations of our planet. For more information, please visit:https://www.astrazeneca.com/country-sites/saudi-arabia.html
Platinum
Boehringer Ingelheim
Improving the health and lives of humans and animals is the goal of the research-driven biopharmaceutical company Boehringer Ingelheim. The focus is on diseases in areas with a high unmet medical need. The company therefore concentrates on developing innovative therapies that can improve and extend lives.
Family-owned since its foundation in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Our aim is to transform the lives of patients – across generations. This goal inspires all of our over 53,000 employees who create value through innovation.
Boehringer Ingelheim is active in the research areas of cardiometabolic diseases, oncology, respiratory diseases, immunology, diseases of the central nervous system and retinal health, The company spent some 5.0 billion euros on research and development worldwide in 2022, with research and development expenses on human pharma alone accounting for 24.8 percent of net sales generated in this area. The global research network for human pharmaceuticals includes facilities in Germany (Biberach and Ochsenhausen), the USA (Ridgefield), Austria (Vienna and Innsbruck), Japan (Kobe) and Switzerland (Basel and Geneva). To learn more, visit: https://www.boehringer-ingelheim.com/mea
GSK
GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together.
We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology. For more information, please visit:https://www.gsk.com/en-gb/locations/saudi-arabia/
Gold
Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and
significantly improve their lives. We strive to set the standard for quality, safety, and value in the
discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. For more information, please visit: www.pfizer.com
Silver
Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.
We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. For more information, please visit: https://www.campus.sanofi
Contributors
Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities, and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body, and environment within reach of everyone, everywhere.
Our vision is to transform pulmonary hypertension into a long-term, manageable condition so that patients can live a normal life. Our long-term commitment to the pulmonary hypertension community: We are with you every step of the journey, no matter how long the road ahead. For more information, please visit: https://www.jnj.com
Sudair Pharmaceutical Company
Sudair Pharmaceutical Company (SPC) is a limited liability Saudi company, established in 2014 in order to build an “Advanced Pharmaceutical Industrial Complex” to fulfil the unmet in the pharmaceutical market with a Vision to improve lives through localizing advanced therapies by increasing the accessibility of high-quality medicinal products, building a professional team to localize and develop a cutting-edge manufacturing technologies.
Sudair Pharma started its mission in KSA & GCC market through building the 1st manufacturing facility in the region dedicated for anti-neoplastic agents (oral & IV) then we expanded our portfolio through building a dedicated site for specialized products that cover different therapy areas like Multiple Sclerosis, Neurology, Anti-coagulation & Pulmonary Hypertension in addition to a wide portfolio for Asthma and CODP management. For more information, please visit: https://sudairpharma.com/
Bayer
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion. A growing and aging world population requires an adequate supply of food and improved medical care.
With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer. All this goes to make up our purpose: Science for a better life. For more information, please visit: www.bayer.com
Biologix
Biologix helps multinational pharmaceutical manufacturers bring innovative drugs to market in the MENA region. Positioned across 17+ key strategic locations in the GCC, Egypt, North Africa and the Levant, we are pioneers in regional distribution and promotion of innovative products and solutions for difficult-to-treat diseases.
A privately owned pharmaceutical company organized under the laws of UAE, Biologix provides end-to-end solutions from the preregistration phase all the way to commercial-scale market access and risk management including: Named patient supply, Pharmaceutical registration, Awareness and promotional campaigns, Cold chain distribution, Tender and risk management, and Pharmacovigilance and product safety.
Incorporated in the Dubai Airport Free Zone in September 2002, Biologix traces its history back to 1997. We were among the first organizations to recognize the need for long-term strategic partnerships in the MENA region, and today we connect pharma leaders around the world with integrated direct-access healthcare approaches. To learn more, visit: https://biologixpharma.com
Anfas Group
Anfas Medical is a leading global company, established in the year 2007 and headquartered in the capital city of Riyadh. The core focus of Anfas Medical lies in the importation of critical intensive respiratory medical equipment, which is subsequently distributed to various medical institutions across Saudi Arabia. The company connected with more than 18 global companies in the domain of medical equipment and spare parts, facilitated through comprehensive distribution agreements. the biggest of them being Hamilton Medical of Switzerland and Ganshorn of Germany.
Furthermore, Anfas Medical has expanded its operations beyond the borders of Saudi Arabia, establishing branches in the United Arab Emirates, Jordan, and Bahrain, thereby fortifying its global presence and enhancing its reach in the healthcare sector. To learn more, Visit: www.anfasmedical.com
Alkawader Scientific Company
Alkawader Scientific Company for Medical Supplies, a limited liability company, was established as per the commercial law of the Kingdom of Saudi Arabia as part of Bahammam group six years ago. Our vision is “to contribute to a future of a high-quality medical care for patients and professionals” while our mission is “Providing and servicing high-quality medical products through unique partnership”. We take pride in our ability to provide high-tech support and expertise required by today’s market. We focus on unique state-of-the-art technologies and therapies which add new tools for diagnoses and treatments for the healthcare community. We currently work in the fields of bronchoscopic navigation, emphysema thermal ablation, MRI safe prostate biopsy robotics, vestibular/balance diagnoses and treatments, rib care reconstruction and pectus correction surgery, and modern sterilization technologies. We also have been supplying state-of-the-art breathing masks and chest drainage systems. For more information, please contact us on: info@kawader-med.com
Exhibitors
taiba access rare
Established in 1980, taiba was the first company in providing medicines for rare diseases in the Middle East. Today, we are the leading company in rare diseases with a diverse, innovative portfolio. Reflecting our commitment to patients, we continue to focus on access to health for patients in our region to reach those in need of our medicines through partnerships. We have the ability and the responsibility to ensure access to medicines through alliances with research and development companies.
Mission:
We strive to transform and save patients’ lives affected by rare diseases in the Middle East and African region by providing innovative medicines and creating meaningful value in all what we do.
Vision:
Our ambition to be the regional reference in orphan drugs, dedicated to providing innovative solutions for unmet medical needs of rare diseases today and in the future.
To learn more, visit: www.taibarare.com
Hikma
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we are helping to shape a healthier world that enriches all our communities. We do this by living our culture, delivering our strategy, and acting responsibly.
We are a trusted, reliable partner and dependable source of over 760+ (as of 31 December 2022) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
We are a global business with 32 manufacturing plants and 8 R&D centres. We are a global company with a local presence in KSA since 1998 and we are producing high quality medicines and making them accessible to the people who need them through our three specialised plants, the general formulation plant, penicillin plant and cephalosporin plant in Riyadh. To learn more, visit: https://www.hikma.com/home/
Gulf Medical Company
Our Mission is to provide state of the art technology and solutions to the healthcare industry in Saudi Arabia and the GCC, and work closely with medical practitioners to contribute to patient care. To play an active role in developing skills of healthcare providers with the support of our suppliers. To evaluate market needs, adapt to changing demands, and continuously enrich our portfolio to effectively focus corporate assets in the service of various disciplines, thus enabling healthy growth. To continue our commitment to offer premium and unique services and ensure ultimate levels of customer satisfaction by recruiting, developing, motivating, and rewarding highly qualified personnel who demonstrate exceptional levels of professionalism and dedication. We believe that making a sale is not the end, but the beginning of a long-lasting relationship which is prized above all. For more information, please visit our website: www.gulfmedical.com
EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals in 40+ countries, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand. For more information, please visit: www.evapharma.com/en-SA
NOVARTIS
NOVARTIS is a leading global pharmaceutical company reimagining medicine to improve people’s lives. We are committed to Saudi society to continue support national health care system with innovative medicines, improve patient access and contribute to National Transformation Plan and Saudi vision 2030.
Novartis worked out a comprehensive localization plan that addresses many economic as well as other transformation measures that go with the government plans like localization of work forces, technology transfers, R&D, support different national healthcare programs and access to innovation.
Novartis had chosen KSA to be one of the first group of worldwide markets to implement cell & gene technologies. For that, we are committed to work with our partners in Saudi Arabia who are among the best health care providers & centers to establish the infrastructure, human capabilities, regulatory environment and technology transfer of this era. Our effort up-to-date made an excellent achievement where on November 2019, the first injected patient of gene therapy outside EU and US was in Saudi Arabia. We are proud of making this for the first time because of collaboration and support of different Saudi government agencies and institutions. For more information, please visit: www.novartis.com/sa-ar/
Mundipharma
Al Naghi
At Mundipharma, our teams are dedicated to our purpose to make a difference when it matters most. Our people enjoy working at Mundipharma because it’s a global organisation that’s caring, collaborative, dynamic and somewhere where they can be themselves.
Building an inclusive environment where people can thrive, grow and achieve their full potential is a priority. We believe this isn’t just the right thing, but also the smart thing to do, as we focus on making a positive difference for our customers and their patients. As an organisation and as individuals, we are continuously learning and improving, and we hold ourselves accountable for doing the right thing at all times.
For more information, please visit: www.mundipharma.com/our-people
Al Naghi Company is an established and highly reputable pharmaceutical and consumer goods distribution company. We continually keep our legacy as a leading force in the distribution of branded pharmaceutical products and fast-moving consumer goods and in the Kingdom of Saudi Arabia. For more information, please visit: www.alnaghi.com
REDAX
In today’s business landscape, the success of a company is largely determined by its capacity to innovate and improve in order to meet the ever-evolving needs of the market.
At Redax, we excel in combining experience and innovation to effectively address clinical requirements. Through continuous collaboration with physicians, engineers, and opinion leaders, we ensure that our products not only meet but surpass expectations. From the initial product prototype to the final marketing stage, we leave no room for chance.
Our Research and Development department has consistently delivered a wide range of drains and continues to offer innovative solutions, constantly enhancing our product catalog at Redax. With our extensive expertise in silicone molding and extrusion processes, we guarantee the highest quality for our silicone drainages available in the market.
We take pride in our internal production processes, which enable us to maintain control over all manufacturing stages. This ensures that we consistently deliver superior quality products, along with fast delivery and competitive costs. By overseeing the entire production process, we maintain a high level of quality control and can swiftly respond to customer demands.
At Redax, our commitment to innovation, collaboration, and quality allows us to meet the evolving needs of the market and provide our customers with superior products and services.
For more information, please visit our website: www.redax.it/en/
Supporters +
Biopharma-mea
At Biopharma-mea, our advanced strategy is to develop and enrich reliable and effective market access for multinational pharmaceutical companies to the Middle East markets, especially in the fields of pioneering biotech pharmaceutical products. We are the catalyst which allows them to successfully introduce their innovative therapies to the Middle Eastern medical landscape which seek to benefit the patients from the advancements in modern biotechnology that these therapies bring.
We strike at the core of serious diseases to change people’s lives. Bringing together the brightest minds, investing in science, and taking smart risks, we go all in. For the lives we have changed and for those who are still waiting, we will never stop fighting until we discover cures. For more information, please visit: www.biopharma-mea.com and www.vrtx.com
AOP Health
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. The claim “Needs. Science. Trust.” sums up the foundation of the Group’s success: establishing trust through a continually high level of investment in research and development and a highly consistent and pragmatic orientation towards the needs of all stakeholders – especially the patients and their families as well as the healthcare professionals treating them. For more information, please visit: www.aop-health.com
Trans-Mediterranean Co
Founded in 2015 with a vision to be one of the leaders in healthcare market in Saudi Arabia by delivering high-quality products and services. Our company has built a strong reputation for reliability and quality by partnering with several esteemed international medical equipment manufacturers and premium customers.
Through strategic collaborations and a skilled workforce, TMT is dedicated to enhancing healthcare delivery kingdom wide through its branches. We are specialized in Respiratory devises and proud to go hand by hand with the leaders in this field. MIR (Medical International Research Co.), the world leading company in Spirometry that provides a wide range of Spirometry devices covering different segments with a unique technologies and smart devices for remote patient monitoring. Geratherm-Respiratory for PFT and Bodybox with German technology and Seoil Pacific Co., specialized in cough assist device (comfort cough).
For mor information, please visit: www.tmt.com.sa
Global Bases Medical Supplies
Founded in 2011 in Jeddah, Global Bases Medical Supplies (GBMS) has quickly established itself as a leading provider in sleep medicine, respiratory therapy, and home healthcare solutions. Our mission from the start has been to deliver cutting-edge healthcare technology across Saudi Arabia.
A pivotal moment in our growth was our strategic partnership with Makamat for Technological Contracting Est. and Philips Healthcare. This alliance has bolstered our reputation and expanded our role in the healthcare industry. Our dedication to innovation and excellence has been key to our success, enabling us to provide exceptional service and build enduring client relationships.
At GBMS, we are committed to “Empowering Healthcare with Trusted Solutions.” As we continue to innovate and advance, we look forward to furthering our legacy of excellence and making a positive impact on the healthcare landscape in Saudi Arabia and beyond. For more information, visit us at: linktr.ee/gbmed and gb.med.sa
